<DOC>
	<DOC>NCT00283751</DOC>
	<brief_summary>This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effective as Insulin Glargine as add-on to current Oral Antidiabetic Drug treatment in reducing HbA1c in patients with Type 2 Diabetes.</brief_summary>
	<brief_title>Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 Diabetes for more than 12 months, and no previous insulin treatment Oral Antidiabetic Drug treatment for at least 4 months Body Mass Index (BMI) less than 40 kg/m2 HbA1c 7.510.0% Current or previous treatment with thiazolidinediones within the last 6 months Oral Antidiabetic Drug treatment with combination of three or more Oral Antidiabetic Drugs within the last 6 months Proliferative retinopathy or maculopathy Known hypoglycaemia unawareness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>